Material Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): December 20, 2024   PROVECTUS BIOPHARMACEUTICALS, INC. (Exact name of registrant as specified in charter)   Delaware   001-36457   90-0031917 (State or other jurisdiction   (Commission   (IRS Employer of incorporation)   File Number)   Identification No.)   800 S. Gay Street , Suite 1610 , Knoxville , Tennessee 37929 (Address of Principal Executive Offices) (Zip Code)   (866) 594-5999 (Registrant’s Telephone Number, Including Area Code)   N/A (Former Name or Former Address, if Changed Since Last Report.)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2 below):   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: None   Title of each class   Trading Symbol(s)   Name of each exchange on which registered             Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01. Entry into a Material Definitive Agreement.   Pursuant to Provectus Biopharmaceuticals, Inc.’s (the “Company’s”) exclusive license agreement with the University of Miami (the “University”) for the development and commercialization of the University’s intellectual property related to photodynamic antimicrobial therapy in ophthalmology entered into on March 21, 2024 (the “License Agreement”) and the approval of the Board of Directors of the Company on December 5, 2024 to transfer certain assets to VisiRose, Inc. (“VisiRose”), a majority-owned subsidiary of the Company focused on the development and commercialization of the Company’s pharmaceutical-grade active pharmaceutical ingredient rose bengal sodium for the treatments of ophthalmology diseases and disorders, the Company and VisiRose entered into an agreement on December 20, 2024 where by the Company assigned the License Agreement to VisiRose, which the University approved (the “Assignment and Assumption Agreement”).   The full text of the Assignment and Assumption Agreement is attached to this Current Report on Form 8-K as Exhibit 10.1 and is incorporated by reference into this Item 1.01.   Item 9.01. Financial Statements and Exhibits.   (d) Exhibits.   Exhibit Number   Description       10.1   Assignment and Assumption Agreement, dated December 20, 2024, by and between the Company and VisiRose and approved by the University 104   Cover Page Interactive Data File (embedded within the Inline XBRL document).         SIGNATURE   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.   Date: December 26, 2024     PROVECTUS BIOPHARMACEUTICALS, INC.         By: /s/ Heather Raines                     Heather Raines     Chief Financial Officer (Principal Financial Officer)